Nasdaq · Healthcare
PRO DEX INC (PDEX)
As-reported financials and recent SEC filings for PRO DEX INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$66.6M
Net income
$9.0M
Net margin
13.5%
Diluted EPS
$2.67
ROE
24.5%
P/E (TTM)
—
Market cap
—
Debt / equity
0.4×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $66.6M | $53.8M | $46.1M | $42.0M | $38.0M |
| Gross profit | $19.5M | $14.6M | $12.7M | $13.1M | $13.6M |
| Operating income | $10.7M | $7.2M | $5.8M | $5.1M | $4.5M |
| Net income | $9.0M | $2.1M | $7.1M | $4.6M | $6.2M |
| Diluted EPS | $2.67 | $0.60 | $1.95 | $1.21 | $1.57 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-06
View on EDGAR →42026-07-06
View on EDGAR →42026-07-06
View on EDGAR →SCHEDULE 13D/A2026-06-26
View on EDGAR →8-K2026-06-17
View on EDGAR →SD2026-06-01
View on EDGAR →42026-05-26
View on EDGAR →1442026-05-21
View on EDGAR →Largest Healthcare peers
Go deeper on PDEX
Search PRO DEX INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.